Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seretide Competition Builds Up But Substitutability Holds Key?

This article was originally published in Scrip

Executive Summary

More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.

You may also be interested in...



Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?

Glenmark-Celon’s generic version of GlaxoSmithKline’s Seretide Accuhaler dry powder inhaler (DPI) has received the go ahead in Germany, upping the competition quotient in a significant market that has generally been seen as tough to penetrate.

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC030137

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel